Approaches to funding: Swedish cost-effectiveness study

Haemophilia

Volumn 4, Issue 4 SUPPL. 1, 1998, Pages 10-12

  Astermark, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE;

ADOLESCENT; ADULT; BLEEDING; CHILD; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; GENE THERAPY; HEALTH CARE FINANCING; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; SWEDEN; TREATMENT OUTCOME;

EID: 0031666013     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.0040s1010.x     Document Type: Conference Paper

References (4)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
2. Pettersson H, Gilbert M. Diagnostic Imaging in Haemophilia; Musculosceletal and Haemorrhagic Complications. Berlin: Springer-Verlag, 1985; 56-65.
3. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of haemophilia A. Eur J Haematol 1993; 51: 247-52.
4. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.